| Indicators | Browse All

Grace Therapeutics, Inc. (GRCE)

Healthcare | Biotechnology | Princeton, United States | NasdaqCM
2.42 USD -0.01 (-0.412%) ⇩ (July 14, 2026, 9:43 a.m. EDT)

Short-term:★★☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 2:56 a.m. EDT

Grace Therapeutics presents a catastrophic long-term investment case driven by a decade-long structural decline. Despite a recent price uptick, the company has lost over 94% of its value since 2016, with five consecutive years of negative annual returns ending just last year. This multi-year trajectory is the definitive signal of deteriorating business quality, rendering any current price recovery irrelevant to the long-term outlook. The fundamentals confirm this distress: the company burns cash aggressively, reports negative returns on equity and assets, and faces severe regulatory hurdles with FDA rejections for its key drug candidates. While the balance sheet currently shows a high current ratio, this is likely propped up by cash reserves rather than operational strength, given the massive free cash flow burn. There is no dividend to provide income, and the stock trades at a fraction of its book value, which often signals deep-seated issues in biotech firms. Short-term, the stock is technically oversold relative to its moving averages, offering a temporary bounce, but the lack of institutional support and the overwhelming options put flow suggest that any rally is fragile. Investors should view this as a speculative gamble on a turnaround that the market has already largely priced out, rather than a viable investment opportunity.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.595376
AutoETS0.627533
MSTL0.642877
AutoTheta0.652571

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 33%
H-stat 0.97
Ljung-Box p 0.000
Jarque-Bera p 0.135
Excess Kurtosis 0.88
Attribute Value
Sector Healthcare
Market Cap 39,383,144
Forward P/E -4.43
Beta 0.37
Previous Name Acasti Pharma Inc.
Website https://www.gracetx.com

As of July 11, 2026, 2:56 a.m. EDT: Speculators are overwhelmingly bearish, with zero call volume and significant put writing across all expirations. The lack of any out-of-the-money call interest suggests a complete absence of bullish speculation, while the heavy put open interest indicates a defensive stance against further downside.


Info Dump

Attribute Value
52 Week Change -0.23824453
Address1 103 Carnegie Center
Address2 Suite 300
All Time High 2,016.0
All Time Low 1.72
Ask 3.05
Ask Size 2
Average Daily Volume10 Day 291,980
Average Daily Volume3 Month 562,439
Average Volume 562,439
Average Volume10Days 291,980
Beta 0.371
Bid 1.73
Bid Size 2
Book Value 3.988
City Princeton
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.42
Current Ratio 8.099
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 2.435
Day Low 2.3901
Display Name Grace Therapeutics
Earnings Timestamp End 1,750,419,000
Earnings Timestamp Start 1,750,419,000
Ebitda -11,070,000
Ebitda Margins 0.0
Enterprise To Ebitda -2.039
Enterprise Value 22,568,884
Eps Current Year -0.737
Eps Forward -0.5467815
Eps Trailing Twelve Months -0.47
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.334
Fifty Day Average Change 0.085999966
Fifty Day Average Change Percent 0.0368466
Fifty Two Week Change Percent -23.824453
Fifty Two Week High 5.18
Fifty Two Week High Change -2.7599998
Fifty Two Week High Change Percent -0.5328185
Fifty Two Week Low 1.79
Fifty Two Week Low Change 0.6300001
Fifty Two Week Low Change Percent 0.35195538
Fifty Two Week Range 1.79 - 5.18
Financial Currency USD
First Trade Date Milliseconds 1,328,625,000,000
Float Shares 13,592,067
Forward Eps -0.5467815
Forward P E -4.4259
Free Cashflow -5,726,125
Full Exchange Name NasdaqCM
Full Time Employees 5
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.2573
Held Percent Institutions 0.26458
Implied Shares Outstanding 16,274,026
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,774,915,200
Last Split Date 1,688,947,200
Last Split Factor 1:6
Long Business Summary Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Long Name Grace Therapeutics, Inc.
Market us_market
Market Cap 39,383,144
Market State REGULAR
Max Age 86,400
Message Board Id finmb_47663822
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-14
Net Income To Common -7,793,000
Next Fiscal Year End 1,806,451,200
Non Diluted Market Cap 39,545,883
Number Of Analyst Opinions 2
Open 2.43
Operating Cashflow -8,869,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 609 322 1602
Prev Name Acasti Pharma Inc.
Previous Close 2.43
Price Eps Current Year -3.2835822
Price Hint 4
Price To Book 0.60682046
Profit Margins 0.0
Quick Ratio 7.92
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.00999999
Regular Market Change Percent -0.41152224
Regular Market Day High 2.435
Regular Market Day Low 2.3901
Regular Market Day Range 2.3901 - 2.435
Regular Market Open 2.43
Regular Market Previous Close 2.43
Regular Market Price 2.42
Regular Market Time 1,784,036,618
Regular Market Volume 7,993
Return On Assets -0.099870004
Return On Equity -0.11943
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 16,274,026
Shares Percent Shares Out 0.10479999
Shares Short 1,705,143
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 2,015,007
Short Name Grace Therapeutics, Inc.
Short Percent Of Float 0.1223
Short Ratio 5.57
Source Interval 15
State NJ
Symbol GRCE
Target High Price 7.9776793
Target Low Price 4.031134
Target Mean Price 6.0044065
Target Median Price 6.0044065
Total Cash 16,977,000
Total Cash Per Share 1.043
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.47
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.2451
Two Hundred Day Average Change -0.82509995
Two Hundred Day Average Change Percent -0.25426024
Type Disp Equity
Volume 7,993
Website https://www.gracetx.com
Zip 8,540